A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
about
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyEfficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceWhat's new for antiretroviral treatment in women with HIVHIV integrase inhibitors: a new era in the treatment of HIV.A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients.Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Single-Tablet Regimens in HIV TherapyResistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutationsHIV treatment and care among Italian inmates: a one-month point survey.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.Cobicistat : a new opportunity in the treatment of HIV disease?The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant virusesElvitegravir for the treatment of HIV.Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials.Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015Dolutegravir: a new option for HIV treatment
P2860
Q26771182-DFE6E75C-1C34-4B4C-BD43-036A4177DFCDQ26783253-6273F360-81D7-4791-A831-1B02F72519ECQ26801286-DF58CDC6-B130-48F1-A7E8-3EA87A66B9BEQ30391322-1C80AAE6-FFF2-4B2E-B499-FC61669146ABQ30956943-9AA69234-8E1A-429C-B9F8-E4F08FFA7533Q30975343-3197EA22-0468-43B6-8E4C-192203B2E006Q33680234-E2104BCA-FF27-4531-A9BA-8B38EA97C3FCQ33939110-CD171ED0-047E-4A98-856B-44FB891EB797Q33963458-60ADBAA5-E2D5-4E57-A483-22BDA8753F04Q35566732-A3D5B4A8-88A7-4167-90D5-A2CFAC59E617Q35607763-6A7AEDFD-E46E-40B9-BF7D-539B9ED9C38FQ35865208-030B4E05-E362-4565-83A9-71C1BA686ECAQ36284159-30392C93-AD99-4F46-9DDD-2344C27242CCQ36571812-7D89519A-3F63-4F69-8FBB-2E06D9236135Q38211165-52D865D5-DC4B-4144-A361-85E5B760CAEEQ38305617-D3BF4377-0668-4B28-9F02-8B0FE6D23C56Q38560855-B44F28DF-510E-4FB9-A672-C0C47671FBAFQ38570500-70D6EC6F-3164-4D3B-9B9E-BF30F0BA170CQ38596011-F84C64E8-02A6-4FDC-996F-D6B87A918E9FQ38774333-D9DD9A63-78B6-40EC-A8F1-2D0343A72072Q38987327-58392A96-188D-4C35-9933-2FCEDB19CA92Q40194507-C8E97CFD-3669-4510-AF01-EA956028A29AQ40516279-7946275C-19F3-4267-9070-517B3DC050DAQ40857943-C11D7884-E745-4759-841E-B7639ECA1A51Q41141601-4DA98DEC-A6EA-41F3-9334-CFBABC55576AQ41465991-5F0FF0D3-8BBB-4F8F-A929-BC92516C0609Q41686477-8F658C1F-B3E9-4AAF-9A63-91ABA3C41574Q42932779-98E644A0-FEB4-49DC-B59D-CBC568086627Q57180790-CFC9A150-1944-48EB-9325-FDBD69A1217FQ58290460-0C7C5202-EC3F-4E40-B244-4A9E6170E244
P2860
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A randomized, double-blind com ...... analysis of week 144 results.
@en
A randomized, double-blind com ...... analysis of week 144 results.
@nl
type
label
A randomized, double-blind com ...... analysis of week 144 results.
@en
A randomized, double-blind com ...... analysis of week 144 results.
@nl
prefLabel
A randomized, double-blind com ...... analysis of week 144 results.
@en
A randomized, double-blind com ...... analysis of week 144 results.
@nl
P2093
P1476
A randomized, double-blind com ...... analysis of week 144 results.
@en
P2093
Edwin DeJesus
GS-236-0103 Study Team
Javier Szwarcberg
Jean-Michel Molina
Joseph Gathe
Keith Henry
Kirsten White
Marshall W Fordyce
Martin S Rhee
Nathan Clumeck
P304
P356
10.1097/QAI.0000000000000089
P407
P577
2014-03-01T00:00:00Z